These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 39189472)

  • 21. Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Li S; Liu Z; Ren Y; Liu J; Lv S; He P; Yang Y; Sun Y; Chang J; Luo D; Cong M
    Front Nutr; 2022; 9():900823. PubMed ID: 35923193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
    Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
    Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
    Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
    Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
    PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
    Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Tan SY; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
    Cancer Immunol Immunother; 2023 Jul; 72(7):1957-1969. PubMed ID: 36811662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers.
    Lilong Z; Kuang T; Li M; Li X; Hu P; Deng W; Wang W
    Clin Nutr; 2024 Jan; 43(1):31-41. PubMed ID: 38000193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between Immune Checkpoint Inhibitor Treatment Outcomes and Body Composition Factors in Metastatic Renal Cell Carcinoma Patients.
    Takei K; Kijima T; Okubo N; Kurashina R; Kokubun H; Uematsu T; Betsunoh H; Yashi M; Kamai T
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive impact of sarcopenia in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A retrospective study.
    Feng Y; Wang L; Guo F; Zhu F; Shi J; Wang Y; Zhang Y; Chen X; Zhang L
    Heliyon; 2024 Mar; 10(5):e27282. PubMed ID: 38463845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE.
    Lim J; Kim KW; Ko Y; Jang IY; Lee YS; Chung YH; Lee HC; Lim YS; Kim KM; Shim JH; Choi J; Lee D
    BMC Cancer; 2021 Oct; 21(1):1164. PubMed ID: 34715813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria.
    Beumer BR; van Vugt JLA; Sapisochin G; Yoon P; Bongini M; Lu D; Xu X; De Simone P; Pintore L; Golse N; Nowosad M; Bennet W; Tsochatzis E; Koutli E; Abbassi F; Claasen MPAW; Merli M; O'Rourke J; Gambato M; Benito A; Majumdar A; Tan EK; Ebadi M; Montano-Loza AJ; Berenguer M; Metselaar HJ; Polak WG; Mazzaferro V; IJzermans JNM;
    J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2373-2382. PubMed ID: 36622940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
    Huang D; Ke L; Cui H; Li S
    BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.
    Zhang L; Chen C; Chai D; Li C; Guan Y; Liu L; Kuang T; Deng W; Wang W
    Front Immunol; 2022; 13():956533. PubMed ID: 36059512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis.
    Wang J; Cao L; Xu S
    Int Immunopharmacol; 2020 Nov; 88():106907. PubMed ID: 33182031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients.
    Long J; Zhang X; Mi W; Shi J; Ren H; Wang Q
    Aging (Albany NY); 2024 Jan; 16(1):389-401. PubMed ID: 38189812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Hou S; Song D; Hao R; Li L; Zhang Y; Zhu J
    Front Immunol; 2024; 15():1382417. PubMed ID: 38966640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review.
    Zhang R; Wang F; You Z; Deng D; He J; Yan W; Quan J; Wang J; Yan S
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):82. PubMed ID: 38319412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
    Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
    Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.